Shortlisted for AIM Awards Technology of the Year

In brief · summary, not quotable

Avacta's pre|CISION® platform shortlisted for AIM Awards Technology of the Year.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes

Avacta's pre				CISION® Platform Shortlisted for the Technology of the Year Award at the AIM Awards
LONDON AND PHILADELPHIA - September 9, 2025 - Avacta Group plc (AIM: AVCT) a life sciences company developing innovative, targeted oncology drugs, is pleased to announce today that its pre				CISION® platform has been shortlisted for the AIM Technology of the Year Award. The AIM Awards is the flagship event for AIM and is held annually, in London, to celebrate success and achievement amongst the world's fastest growing publicly quoted companies. The Awards identify the quoted companies and entrepreneurs who have harnessed AIM to help them fulfil their ambition and growth potential in the last twelve months. The Awards will be distributed at the event on October 1, 2025.
Christina Coughlin, CEO of Avacta commented:
"We are delighted to be on the shortlist for Technology of the Year among companies listed on the AIM market. Our pre				CISION® technology changes the way that potent cancer therapies are delivered to patients, where the drug is silent in the bloodstream yet active in the tumor, allowing cancer cells to be targeted while preserving patient vitality. We look forward to the event next month."
About the pre				CISION® Platform
The pre	CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre	CISION® platform harnesses this tumor specific protease to cleave pre	CISION® peptide drug conjugates and pre	CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.